Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 6/20/2025

Management of Relapsed Chronic Myeloid Leukemia (CML)

Introduction to Major Molecular Response (MMR)

  • Major molecular response is defined as BCR-ABL1 transcript levels ≤0.1% on the International Scale (IS), representing a critical treatment goal for relapsed CML patients, as per the National Comprehensive Cancer Network (NCCN) guidelines 1, 2
  • The achievement of MMR in relapsed CML patients has substantial clinical implications, including reduced risk of disease progression and improved overall survival outcomes 1, 3, 2

Initial Assessment and Treatment Selection

  • Check compliance with previous tyrosine kinase inhibitor (TKI) therapy and perform BCR-ABL1 mutation analysis to guide treatment selection, with consideration of increasing imatinib to 600-800 mg/day for mildly resistant mutations (IC50 < 5-fold of unmutated BCR-ABL) and switching to broader-spectrum TKI (dasatinib, nilotinib, ponatinib) for highly resistant mutations (IC50 > 10-fold of unmutated BCR-ABL) 4
  • The Sokal risk score at diagnosis significantly impacts response rates, with low-risk patients having higher rates of both Complete Cytogenetic Response (CCyR) and MMR, and high-risk patients having lower rates of both responses 5

Response Monitoring and Treatment Decisions

  • Monitor BCR-ABL1 transcript levels every 3 months and perform bone marrow cytogenetics every 3 months until CCyR is achieved, with consideration of treatment change if no MMR by 12 months or if loss of MMR occurs 1, 4, 6, 5
  • Early molecular response with BCR-ABL1 transcript levels ≤10% at 3 months is the strongest predictor of both MMR and CCyR, with achievement of CCyR being the most clinically significant milestone for survival outcomes in CML patients 6, 5
  • Failure to achieve ≤10% BCR-ABL1 at 3 months or CCyR by 12 months should prompt consideration of treatment change, according to the NCCN guidelines 5, 6

Deep Molecular Response and Treatment-Free Remission (TFR)

  • Deep molecular response definitions include MR4 (BCR-ABL1 ≤0.01% IS), MR4.5 (BCR-ABL1 ≤0.0032% IS), and MR5 (BCR-ABL1 ≤0.001% IS), with patients who achieve and maintain deep molecular response (≥MR4.0) for ≥2 years being candidates for TFR, approximately 40-60% of patients maintaining TFR after discontinuation 1, 5
  • Achievement of MMR at 12 months is associated with a very low probability of subsequent response loss and a high likelihood of achieving deep molecular response, making TFR an important goal 5

Allogeneic Stem Cell Transplantation and Monitoring Frequency

  • Consider allogeneic stem cell transplantation for patients who fail multiple TKI therapies, with more intensive monitoring required for relapsed patients, including monthly PCR testing for the first 6 months after treatment change, every 2 months for the subsequent 6 months, and every 3 months thereafter 4, 5
  • The rate of decline in BCR-ABL1 transcripts correlates with longer-term response, with a BCR-ABL1 halving time <76 days with imatinib associated with superior outcomes (4-year PFS rate 92% vs 63%) 5

Laboratory Considerations and Treatment Adherence

  • Ensure laboratory uses standardized IS reporting with adequate sensitivity (at least MR4.5), and assess treatment adherence before changing therapy, as non-adherence is a major cause of suboptimal response and relapse, according to the NCCN guidelines 5, 6
  • Complete Molecular Response (CMR) is defined as no detectable BCR-ABL1 transcripts by RT-PCR with a sensitivity threshold of 10^-4 to 10^-5, with achievement of CMR by 3 months associated with significantly longer median overall survival (127 months vs. 38 months for those without CMR, p=0.009) and reduced risk of transformation to accelerated or blast phase 2, 3
  • Quantitative RT-PCR is the most sensitive assay available for BCR-ABL chimeric mRNA, capable of detecting one CML cell in 100,000 normal cells, according to the NCCN guidelines 6
  • CMR should be confirmed with at least two consecutive negative PCR tests, and maintaining CMR provides the best long-term protection against disease progression, with treatment continuation recommended for patients not interested in treatment discontinuation, as stated by the NCCN guidelines 2, 6
Response Definition
Complete Cytogenetic Response (CCyR) 0% Ph+ metaphases
Major Molecular Response (MMR) BCR-ABL1 ≤0.1% IS
Deep Molecular Response MR4 (BCR-ABL1 ≤0.01% IS), MR4.5 (BCR-ABL1 ≤0.0032% IS), MR5 (BCR-ABL1 ≤0.001% IS)
Complete Molecular Response (CMR) No detectable BCR-ABL1 transcripts by RT-PCR with a sensitivity threshold of 10^-4 to 10^-5